Detalles de la búsqueda
1.
Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR.
Osteoporos Int
; 31(1): 203-207, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31641801
2.
Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study.
Int J Obes (Lond)
; 40(7): 1157-63, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27143035
3.
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Diabetes Obes Metab
; 18(1): 40-8, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26343931
4.
Is insulin the most effective injectable antihyperglycaemic therapy?
Diabetes Obes Metab
; 17(2): 145-51, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25323312
5.
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Diabetes Obes Metab
; 17(10): 965-73, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25980900
6.
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.
Diabetes Obes Metab
; 17(5): 505-10, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25656522
7.
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Diabetes Obes Metab
; 17(6): 560-565, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25728612
8.
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.
Diabetes Obes Metab
; 17(5): 477-86, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25656058
9.
Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Diabetes Obes Metab
; 16(12): 1247-56, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25109825
10.
Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Diabetes Obes Metab
; 16(11): 1065-9, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24840317
11.
Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
Diabetes Obes Metab
; 16(3): 206-14, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23711193
12.
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Diabet Med
; 30(11): 1293-7, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23710902
13.
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Diabetes Obes Metab
; 15(1): 42-54, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22862847
14.
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.
Diabetologia
; 55(6): 1641-50, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22450889
15.
Factitious ACTH-dependent, apparent hypercortisolism: The problem with late-night salivary cortisol measurements collected at home.
Clin Endocrinol (Oxf)
; 87(6): 882-885, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28929506
16.
Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.
Diabet Med
; 28(6): 715-23, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21388442
17.
Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses.
J Exp Med
; 159(6): 1629-36, 1984 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-6202817
18.
Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats.
J Exp Med
; 162(2): 444-58, 1985 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-2991415
19.
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetologia
; 52(1): 17-30, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18941734
20.
The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex.
Science
; 231(4739): 733-5, 1986 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-3003909